205 related articles for article (PubMed ID: 17989779)
1. Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin.
Schütte D; Um-Boock A; Mensah-Quainoo E; Itin P; Schmid P; Pluschke G
PLoS Negl Trop Dis; 2007 Oct; 1(1):e2. PubMed ID: 17989779
[TBL] [Abstract][Full Text] [Related]
2. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions.
Schütte D; Umboock A; Pluschke G
Br J Dermatol; 2009 Feb; 160(2):273-83. PubMed ID: 19016694
[TBL] [Abstract][Full Text] [Related]
3. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?
Ruf MT; Chauty A; Adeye A; Ardant MF; Koussemou H; Johnson RC; Pluschke G
PLoS Negl Trop Dis; 2011 Aug; 5(8):e1252. PubMed ID: 21829740
[TBL] [Abstract][Full Text] [Related]
4. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).
Yotsu RR; Richardson M; Ishii N
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012118. PubMed ID: 30136733
[TBL] [Abstract][Full Text] [Related]
5. Secondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin.
Yeboah-Manu D; Kpeli GS; Ruf MT; Asan-Ampah K; Quenin-Fosu K; Owusu-Mireku E; Paintsil A; Lamptey I; Anku B; Kwakye-Maclean C; Newman M; Pluschke G
PLoS Negl Trop Dis; 2013; 7(5):e2191. PubMed ID: 23658847
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
[TBL] [Abstract][Full Text] [Related]
7. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
Tanywe A; Fernandez RS
JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
[TBL] [Abstract][Full Text] [Related]
10. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).
Chauty A; Ardant MF; Adeye A; Euverte H; Guédénon A; Johnson C; Aubry J; Nuermberger E; Grosset J
Antimicrob Agents Chemother; 2007 Nov; 51(11):4029-35. PubMed ID: 17526760
[TBL] [Abstract][Full Text] [Related]
11. Buruli Ulcer: Review of a Neglected Skin Mycobacterial Disease.
Guarner J
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29343539
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.
Klis S; Kingma RA; Tuah W; van der Werf TS; Stienstra Y
Trop Med Int Health; 2016 Sep; 21(9):1191-6. PubMed ID: 27456068
[TBL] [Abstract][Full Text] [Related]
13. Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.
Martins TG; Gama JB; Fraga AG; Saraiva M; Silva MT; Castro AG; Pedrosa J
PLoS One; 2012; 7(2):e32740. PubMed ID: 22393444
[TBL] [Abstract][Full Text] [Related]
14. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.
Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L
BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095
[TBL] [Abstract][Full Text] [Related]
15. Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.
Sarfo FS; Converse PJ; Almeida DV; Zhang J; Robinson C; Wansbrough-Jones M; Grosset JH
PLoS Negl Trop Dis; 2013; 7(3):e2101. PubMed ID: 23516649
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Streptomycin-Rifampicin treatment of Buruli Ulcer in two Ghanaian districts.
Iddrisah FN; Yeboah-Manu D; Nortey PA; Nyarko KM; Anim J; Antara SN; Kenu E; Wurapa F; Afari EA
Pan Afr Med J; 2016; 25(Suppl 1):13. PubMed ID: 28149438
[TBL] [Abstract][Full Text] [Related]
17. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
[TBL] [Abstract][Full Text] [Related]
18. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
Phillips RO; Robert J; Abass KM; Thompson W; Sarfo FS; Wilson T; Sarpong G; Gateau T; Chauty A; Omollo R; Ochieng Otieno M; Egondi TW; Ampadu EO; Agossadou D; Marion E; Ganlonon L; Wansbrough-Jones M; Grosset J; Macdonald JM; Treadwell T; Saunderson P; Paintsil A; Lehman L; Frimpong M; Sarpong NF; Saizonou R; Tiendrebeogo A; Ohene SA; Stienstra Y; Asiedu KB; van der Werf TS;
Lancet; 2020 Apr; 395(10232):1259-1267. PubMed ID: 32171422
[TBL] [Abstract][Full Text] [Related]
19. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).
Kibadi K; Boelaert M; Fraga AG; Kayinua M; Longatto-Filho A; Minuku JB; Mputu-Yamba JB; Muyembe-Tamfum JJ; Pedrosa J; Roux JJ; Meyers WM; Portaels F
PLoS Negl Trop Dis; 2010 Jul; 4(7):e736. PubMed ID: 20625556
[TBL] [Abstract][Full Text] [Related]
20. Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms.
Sopoh GE; Dossou AD; Brun LV; Barogui YT; Houézo JG; Affolabi D; Anagonou SY; Johnson RC; Kestens L; Portaels F
Am J Trop Med Hyg; 2010 Aug; 83(2):307-13. PubMed ID: 20682873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
